The progression & delivery of adoptive cellular immune therapies

Resources > Immuno-Oncology > The progression & delivery of adoptive cellular immune therapies

The progression & delivery of adoptive cellular immune therapies

2020  |  Vicki Moignard, Alessandra De Riva & Raul Elgueta

The success and progression of chimeric antigen receptor (CAR) T cells in adoptive cellular therapies for B cell malignancies can be attributed to the effective engraftment, efficient expansion, and persistence of the cells after transplant. However, that success has yet to be translated into solid tumors, which present their own set of distinct challenges. As the knowledge in the field grows and more data reach the public domain, it has become clear that both intrinsic and extrinsic mechanisms of tumor resistance need to be addressed in order to improve immune-based adoptive cell therapies (ACT). Computational approaches and novel algorithms are well placed to identify new genes needed to overcome resistance and enhance the efficacy of the current and future ACT. This review discusses the current challenges for autologous and allogeneic ACT and how big dataset analysis is opening paths to overcome resistance and enhance the efficacy of ACT.

View all resources
Go to Top